Erste Asset Management GmbH Purchases 600,000 Shares of Biohaven Ltd. $BHVN

Erste Asset Management GmbH boosted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 643.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 693,300 shares of the company’s stock after buying an additional 600,000 shares during the period. Erste Asset Management GmbH owned approximately 0.65% of Biohaven worth $7,851,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Aberdeen Group plc bought a new position in Biohaven during the fourth quarter valued at approximately $7,829,000. Capital Research Global Investors lifted its stake in shares of Biohaven by 108.9% in the 3rd quarter. Capital Research Global Investors now owns 1,011,530 shares of the company’s stock valued at $15,183,000 after purchasing an additional 527,337 shares during the last quarter. Integral Health Asset Management LLC lifted its stake in shares of Biohaven by 116.7% in the 3rd quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $9,756,000 after purchasing an additional 350,000 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Biohaven by 291.8% in the 4th quarter. SG Americas Securities LLC now owns 105,518 shares of the company’s stock valued at $1,191,000 after purchasing an additional 78,585 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Biohaven by 484.7% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 133,900 shares of the company’s stock valued at $1,512,000 after purchasing an additional 111,000 shares during the last quarter. 88.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen lowered Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Royal Bank Of Canada lowered their price objective on Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Citigroup raised their price objective on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Morgan Stanley lowered their price objective on Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 price objective on shares of Biohaven in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Biohaven has an average rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Price Performance

Shares of BHVN stock opened at $11.12 on Tuesday. Biohaven Ltd. has a 52-week low of $7.48 and a 52-week high of $18.57. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The firm has a market capitalization of $1.67 billion, a P/E ratio of -1.96 and a beta of 1.35. The stock has a 50 day moving average price of $9.79 and a 200 day moving average price of $10.46.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). As a group, sell-side analysts predict that Biohaven Ltd. will post -3.03 earnings per share for the current year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.